Medindia

X

ArQule Inc Reveals Experimental Colorectal Cancer Drug Fails to Extend Survival in Trial

by Kathy Jones on  January 12, 2013 at 8:02 PM Cancer News   - G J E 4
American drug maker ArQule Inc revealed that its experimental colorectal cancer drug, developed in collaboration with Japan's Daiichi Sankyo Co Ltd, has failed to achieve its main goal of extending the progression-free survival period in patients in a trial.
 ArQule Inc Reveals Experimental Colorectal Cancer Drug Fails to Extend Survival in Trial
ArQule Inc Reveals Experimental Colorectal Cancer Drug Fails to Extend Survival in Trial
Advertisement

The experimental drug, known as tivantinib, was ArQule's lead candidate with the company also hoping that the drug could be used in treating hepatocellular carcinoma or liver cancer.

Advertisement
The company said that while the drug was able to slightly improve the progression free survival period in the trial, which included 122 patients with refractory or relapsed colorectal cancer, the improvement was not significant enough.

Daiichi's Reinhard von Roemeling tried to remain positive, stating that they will now be looking at how to best proceed in improving the drug. "We are encouraged by these findings. We plan to continue discussions to determine how best to proceed with further clinical development of tivantinib in this tumor type", he said.

Source: Medindia
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

Advertisement
View All